HBV associated nephrotic syndrome: Resolution with oral lamivudine

Archives of Disease in Childhood

Volumn 88, Issue 5, 2003, Pages 446-449

  Connor, F L ^a   Rosenberg, A R ^a   Kennedy, S E ^a   Bohane, T D ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; HEPATITIS B ANTIGEN; HEPATITIS B CORE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; SERUM ALBUMIN;

ANAMNESIS; ANOREXIA; ARTICLE; CASE REPORT; CLUBBING FINGERS; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; FEVER; FOLLOW UP; HEMATURIA; HEPATITIS B; HEPATITIS B VIRUS; HEPATOMEGALY; HUMAN; HUMAN TISSUE; IMMUNIZATION; LABORATORY TEST; LETHARGY; LIVER FUNCTION TEST; MEMBRANOUS GLOMERULONEPHRITIS; NEPHROTIC SYNDROME; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEINURIA; SIDE EFFECT; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTIGENS, VIRAL; CHILD; GLOMERULONEPHRITIS, MEMBRANOUS; HEPATITIS B; HUMANS; LAMIVUDINE; MALE; MICROSCOPY, ELECTRON; NEPHROTIC SYNDROME; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0037509931     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.88.5.446     Document Type: Article

References (52)

1. Shapiro RJ, Steinbrecher UP, Magil A. Remission of nephrotic syndrome of HBV-associated membranous glomerulopathy following treatment with interferon. Am J Nephrol 1995;15:343-7.
2. Wong SN, Yu EC, Chan KW. Hepatitis B virus associated membranous glomerulonephritis in children - experience in Hong Kong. Clin Nephrol 1993;40:142-7.
3. Giboa N, Neigut D. Interferon treatment of hepatitis B-associated membranous glomerulonephritis and nephrotic syndrome. Pediatr Nephrol 1993;7:328-9.
4. Lidman C, Magnius L, Norder H, et al. Interferon alpha-2b treatment in an HIV-infected patient with hepatitis B virus induced nephrotic syndrome. Scand J Infect Dis 1993;25:133-5.
5. Wong SN, Yu EC, Lok AS, et al. Interferon treatment for hepatitis B-associated membranous glomerulonephritis in two Chinese children. Pediatr Nephrol 1992;6:417-20.
6. de Man RA, Schalm SW, van der Heijden AJ, et al. Improvement of hepatitis B-associated glomerulonephritis after antiviral combination therapy. J Hepatol 1989;8:367-72.
7. Lopes Neto EP, Lopes LV, Kirsztajn GM, et al. Alpha-interferon therapy for HBV-related glomerulonephritis. Rev Paul Med 1998;116:1823-5.
8. Lin CY. Treatment of hepatitis B virus-associated membranous nephropathy with recombinant alpha-interferon. Kidney Int 1995;47:225-30.
9. McMahon B, Alward W, Hall D, et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent carrier state. J Infect Dis 1985;151:599-603.
10. Bortolotti F, Jara P, Crivellaro C, et al. Outcome of chronic hepatitis B in Caucasian children during a 20-year observation period. J Hepatol 1998;29:184-90.
11. Yang H, Sheng-Nan L, Liaw Y, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002;347:168-74.
12. Bhimma R, Coovadia HM, Adhikari M. Nephrotic syndrome in South African children: changing perspectives over 20 years. Pediatr Nephrol 1997;11:429-34.
13. Nagy J, Bajtai G, Brasch H, et al. The role of hepatitis B surface antigen in the pathogenesis of glomerulopathies. Clin Nephrol 1979;12:109-16.
14. Abdurrahman MB, Fakunle YM, Whittle HC. The role of hepatitis B surface antigen in Nigerian children with nephrotic syndrome. Ann Trop Paediatr 1983;3:13-16.
15. Takekoshi Y, Tanaka M, Miyakawa Y, et al. Free "small" and IgG-associated "large" hepatitis B e antigen in the serum and glomerular capillary walls of two patients with membranous glomerulonephritis. N Engl J Med 1979;300:814-19.
16. Lin CY. Hepatitis B virus, associated membraneous nephropathy: clinical features, immunological profiles and outcome. Nephron 1990;55:37-44.
17. Yoshikawa N, ho H, Yamada Y, et al. Membranous glomerulonephritis associated with hepatitis B antigen in children: a comparison with idiopathic membranous glomerulonephritis. Clin Nephrol 1985;23:28-34.
18. Lai KN, Ho RT, Tam JS, et al. Detection of hepatitis B virus DNA and RNA in kidneys of HBV related glomerulonephritis. Kidney Int 1996;50:1965-77.
19. Bhimma R, Coovadia HM, Adhikari M. Hepatitis B virus-associated nephropathy in black South African children. Pediatr Nephrol 1998;12:479-84.
20. Gilbert RD, Wiggelinkhuizen J. The clinical course of hepatitis B virus-associated nephropathy. Pediatr Nephrol 1994;8:11-14.
21. Lai KN, Li PK, Lui SF, et al. Membranous nephropathy related to hepatitis B virus in adults. N Engl J Med 1991;324:1457-63.
22. Bhimma R, Coovadia HM, Kramvis A, et al. Treatment of hepatitis B virus-associated nephropathy in black children. Pediatr Nephrol 2002;17:393-9.
23. Abbas NA, Pitt MA, Green AT, et al. Successful treatment of hepatitis B virus (HBV)-associated membranoproliferative glomerulonephritis (MPGN) with alpha interferon. Nephrol Dial Transplant 1999;14:1272-5.
24. Di Bisceglie AM. Long-term outcome of interferon-alpha therapy for chronic hepatitis B. J Hepatol 1995;22:65-7.
25. Sokal E, Conjeevaram H, Roberts E, et al. Interferon alpha for treatment of pediatric chronic hepatitis B: a randomised multicenter trial. Gastroenterology 1998;114:988-95.
26. Ruiz-Moreno M, Rua M, Molina J, et al. Prospective, randomized, controlled trial of IFN alpha in children with chronic hepatitis B. Hepatology 1991;13:1035-9.
27. Barbera C, Bortolotti F, Crivellaro C, et al. Recombinant interferon alpha 2a hastens the rate of HBeAg clearance in children with chronic hepatitis B. Hepatology 1994;20:287-90.
28. Gregorio M, Jara P, Hierro L, et al. Lymphoblastoid interferon alpha with or without steroid pretreatment in children with chronic hepatitis B: a multicentre controlled trial. Hepatology 1996;23:700-7.
29. Bortolotti F, Jara P, Barbera C, et al. Long term effect of alpha interferon in children with chronic hepatitis B. Gut 2000;46:715-18.
30. Sokal EM, Roberts EA, Mieli-Vergani G, et al. A dose ranging study of the pharmacokinetics, safety, and preliminary efficacy of lamivudine in children and adolescents with chronic hepatitis B. Antimicrob Agents Chemother 2000;44:590-7.
31. Lacaille F. Lamivudine treatment for children with interferon refractory chronic hepatitis B. Hepatology 2000;32:1180.
32. Kocak N, Ozen H, Saltik IN, et al. Lamivudine for children with chronic hepatitis B. Am J Gastroenterol 2000;95:2989-90.
33. Kocak N, Saltik IN, Ozen H, et al. Lamivudine treatment for children with interferon refractory chronic hepatitis B. Hepatology 2000;31:545.
34. Dikici B, Bosnak M, Kara IH, et al. Lamivudine and interferon-alpha combination treatment of childhood patients with chronic hepatitis B infection. Pediatr Infect Dis J 2001;20:988-92.
35. Shapira R, Mor E, Bar-Nathan N, et al. Efficacy of lamivudine for the treatment of hepatitis B virus infection after liver transplantation in children. Transplantation 2001;72:333-6.
36. Jonas MM, Kelley DA, Mizerski J, et al. Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med 2002;346:1706-13.
37. Schalm SW, Heathcote J, Cianciara J, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000;46:562-8.
38. Allen MI, Deslauriers M, Andrews CW, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998;27:1670-7.
39. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-63.
40. Leung NW, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001;33:1527-32.
41. Yuen MF, Sablon E, Hui CK, et al. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001;34(4 pt 1):785-91.
42. Serfaty L, Thabut D, Zoulim F, et al. Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: results of a pilot study. Hepatology 2001;34:573-7.
43. Gupta S, Piraka C, Jaffe M. Lamivudine in the treatment of polyarteritis nodosa associated with acute hepatitis B. N Engl J Med 2001;344:1645-6.
44. Deleaval P, Stadler P, Descombes E, et al. Life-threatening complications of hepatitis B virus-related polyarteritis nodosa developing despite interferon-alpha2b therapy: successful treatment with a combination of interferon, lamivudine, plasma exchanges and steroids. Clin Rheumatol 2001;20:290-2.
45. Bedani PL, Bergami M, Cavazzini PL, et al. HBV-related cutaneous periarteritis nodosa in a patient 16 years after renal transplantation: efficacy of lamivudine. J Nephrol 2001;14:428-30.
46. Viani RM, Dankner WM, Muelenaer PA, et al. Resolution of HIV-associated nephrotic syndrome with highly active antiretroviral therapy delivered by gastrostomy tube. Pediatrics 1999;104:1394-6.
47. Chien RN, Liaw YF, Atkins M. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group. Hepatology 1999;30:770-4.
48. Al-Wakeel J, Mitwalli A, Tarif N, et al. Role of interferon-alpha in the treatment of primary glomerulonephritis. Am J Kidney Dis 1999;33:1142-6.
49. Lin CY, Lin CC, Chang GJ, et al. Defect of cell-mediated immune response against hepatitis B virus: an indication for pathogenesis of hepatitis-B-virus-associated membranous nephropathy. Nephron 1997;76:176-85.
50. Ishikawa T, Kakumu S, Yoshioka K, et al. Effects of interferon-alpha treatment on hepatitis B virus antigen-specific immunologic responses in patients with chronic hepatitis B. Liver 1993;13:95-101.
51. Boni C, Bertoletti A, Penna A, et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 1998;102:968-75.
52. Boni C, Penna A, Ogg GS, et al. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology 2001;33:963-71.